Want to see IN:CONCORDBIO full AI Analyst Report?
CONCORDBIO Stock Chart & Stats
₹1248.65
₹7.90(0.63%)
At close: 4:00 PM EDT
₹1248.65
₹7.90(0.63%)
Day’s Range― - ―
52-Week Range₹987.05 - ₹1,800.00
Previous CloseN/A
Volume79.36K
Average Volume (3M)12.81K
Market Cap
₹143.07B
Enterprise Value₹101.96K
Total Cash (Recent Filing)₹4.16B
Total Debt (Recent Filing)₹23.16M
Price to Earnings (P/E)54.1
Beta1.20
Next Earnings
Nov 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.53%
Share Statistics
EPS (TTM)24.86
Shares Outstanding104,616,200
10 Day Avg. Volume31,605
30 Day Avg. Volume12,808
Financial Highlights & Ratios
PEG Ratio-1.36
Price to Book (P/B)5.32
Price to Sales (P/S)10.16
P/FCF Ratio61.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)31.76
Revenue Forecast (FY)₹12.60B
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExceptionally low leverage and rising equity give the company durable financial flexibility. Minimal debt reduces refinancing risk, supports steady capex or R&D funding, and enhances resilience to industry cycles, enabling long-term investment in fermentation capabilities.
Sustained Profitability And MarginsConsistently healthy gross and net margins indicate structural pricing power in complex fermentation-based APIs. Strong operating margins support reinvestment, sustained cash generation and competitive returns, reinforcing the firm's ability to compete in specialized therapeutic segments.
Consistent Operating Cash GenerationOperating cash flow that regularly exceeds net income signals earnings quality and reliable internal funding for capex and product development. The recent FCF rebound strengthens liquidity and reduces dependence on external financing for growth in APIs and process scale-up.
Bears Say
Recent Revenue DeclineA material revenue decline after years of expansion suggests structural demand headwinds or customer-side volatility. Sustained top-line contraction would constrain reinvestment capacity, pressure margins over time, and could signal weakening share or order visibility in key API markets.
Margin Compression Versus Peak YearsMargins retreating from prior peaks point to cost pressures, pricing erosion, or product mix shifts. If sustained, margin compression will reduce free cash flow conversion and ROI on manufacturing investments, limiting the company's ability to expand capacity or fund higher-margin R&D.
Volatile Free Cash Flow HistoryIntermittent negative FCF and swings in free cash flow reflect variability in working capital or reinvestment timing. This volatility complicates long-range planning and can stress funding for capital projects or partnerships during downturns despite recent improvements.
Concord Biotech Ltd. News
CONCORDBIO FAQ
What was Concord Biotech Ltd.’s price range in the past 12 months?
Concord Biotech Ltd. lowest stock price was ₹987.05 and its highest was ₹1800.00 in the past 12 months.
What is Concord Biotech Ltd.’s market cap?
Concord Biotech Ltd.’s market cap is ₹143.07B.
When is Concord Biotech Ltd.’s upcoming earnings report date?
Concord Biotech Ltd.’s upcoming earnings report date is Nov 18, 2026 which is in 98 days.
How were Concord Biotech Ltd.’s earnings last quarter?
Concord Biotech Ltd. released its earnings results on Jul 31, 2026. The company reported ₹5.6 earnings per share for the quarter, missing the consensus estimate of ₹7.333 by -₹1.733.
Is Concord Biotech Ltd. overvalued?
According to Wall Street analysts Concord Biotech Ltd.’s price is currently Overvalued.
Does Concord Biotech Ltd. pay dividends?
Concord Biotech Ltd. pays a Annually dividend of ₹7.55 which represents an annual dividend yield of 0.53%. See more information on Concord Biotech Ltd. dividends here
What is Concord Biotech Ltd.’s EPS estimate?
Concord Biotech Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Concord Biotech Ltd. have?
Concord Biotech Ltd. has 104,616,200 shares outstanding.
What happened to Concord Biotech Ltd.’s price movement after its last earnings report?
Concord Biotech Ltd. reported an EPS of ₹5.6 in its last earnings report, missing expectations of ₹7.333. Following the earnings report the stock price went up 6.533%.
Which hedge fund is a major shareholder of Concord Biotech Ltd.?
Currently, no hedge funds are holding shares in IN:CONCORDBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Concord Biotech Ltd.
Concord Biotech Limited, a biopharma company, engages in the research and development, manufacture, market, and sale of pharmaceutical products in India and internationally. The company provides fermentation based active pharmaceutical ingredients in immunosuppressants, anti-bacterial, oncology, antifungal, and other therapeutic areas. It also offers tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus for immunosuppressants therapeutic segment; and temsirolimus, everolimus, romidepsin, doxorubicin, mitomycin, midostaurin, and dactinomycin for oncology therapeutic segment. In addition, the company provides mupirocin, mupirocin calcium, polymyxin B sulfate, fidaxomicin, vancomycin hydrochloride, and teicoplanin for anti-bacterial applications; anidulafungin, caspofungi, micafungin sodium, and nystatin for anti-fungal therapeutic segment; and lovastatin and pravastatin sodium for other applications. Further, it develops daptomycin for anti-infectives applications; and epirubicin, idarubicin, and pirarubicin for oncology therapeutic segment. Additionally, the company provides contract research and manufacturing services in the areas of fermentation and semi-synthesis products. Concord Biotech Limited was incorporated in 1984 and is based in Ahmedabad, India.
Technical Analysis
Biocon Limited
―
Dishman Carbogen Amcis Ltd.
―
Panacea Biotec Limited
―
Syngene International Ltd.
―
Anthem Biosciences Limited
―